PMV Pharmaceuticals Appoints Industry Veteran Dr. Carol Gallagher to Board of Directors
04 nov. 2022 08h00 HE
|
PMV Pharmaceuticals, Inc.
CRANBURY, N.J., Nov. 04, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
PMV Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate Highlights
09 août 2022 08h00 HE
|
PMV Pharmaceuticals, Inc.
Initial PC14586 Phase 1 data presented at the American Society of Clinical Oncology Annual Meeting (ASCO) demonstrated responses in patients across multiple solid tumor types with a p53 Y220C...
PMV Pharmaceuticals Announces a Clinical Trial Collaboration with Merck to Evaluate PC14586 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
18 juil. 2022 08h00 HE
|
PMV Pharmaceuticals, Inc.
CRANBURY, N.J., July 18, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule,...
PMV Pharmaceuticals to Participate in the Goldman Sachs Global Healthcare Conference
08 juin 2022 08h00 HE
|
PMV Pharmaceuticals, Inc.
CRANBURY, N.J., June 08, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule,...
PMV Pharmaceuticals Initial PC14586 Phase 1 Data Presented at ASCO Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a p53 Y220C Mutation
07 juin 2022 12h00 HE
|
PMV Pharmaceuticals, Inc.
Overall response rate (ORR) of 32% (8/25) achieved in higher dose cohorts per RECIST v1.1 Partial responses observed across six distinct tumor typesData featured as an oral presentation at ASCO;...
PMV Pharmaceuticals Announces Initial PC14586 Phase 1 Clinical Data to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
26 mai 2022 17h05 HE
|
PMV Pharmaceuticals, Inc.
Preliminary results represent the first clinical evidence of targeting a p53 Y220C mutation ASCO abstract highlights 3/10 (30%) partial responses in patients treated in higher dose cohorts and...
PMV Pharmaceuticals Reports First Quarter 2022 Financial Results and Corporate Highlights
10 mai 2022 07h30 HE
|
PMV Pharmaceuticals, Inc.
Oral presentation at 2022 ASCO annual meeting to highlight initial data from ongoing Phase 1/2 PYNNACLE study of PC14586 in patients with advanced solid tumors CRANBURY, N.J., May 10, 2022...
PMV Pharmaceuticals to Present PC14586 Phase 1 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
27 avr. 2022 10h30 HE
|
PMV Pharmaceuticals, Inc.
Oral presentation at ASCO to highlight initial data from ongoing Phase 1 study of PC14586, a first-in-class precision oncology investigational therapy, in patients with advanced solid tumors that have...
PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights
01 mars 2022 07h15 HE
|
PMV Pharmaceuticals, Inc.
Continued progress with Phase 1/2 study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors that have a p53 Y220C mutationStrong cash, cash...
PMV Pharmaceuticals to Participate in the 42nd Annual Cowen Health Care Conference
28 févr. 2022 08h00 HE
|
PMV Pharmaceuticals, Inc.
CRANBURY, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...